Juan Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan Feng has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Xian Wang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, People’s Republic of China
15 shared publications Xian Wang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China
12 shared publicationsBo Liu
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China
8 shared publicationsJuan Yang
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China
8 shared publicationsXiaolong Ma
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China
8 shared publicationsLulu Han
Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, China; Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China
7 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (33)
GNPs-pIL-4 reprograms macrophage polarization and activates the OSM/GSNOR/ENG axis to improve angiogenesis in ischemic limbs
Therapeutic angiogenesis based on gene therapies is a potential peripheral artery disease (PAD) treatment yet needs a more stable, efficient, and high-affinity delivery vector and an optimized delivery strategy. Here, we engineered three-dimensional graphene nanoparticles modified with folic acid and polyethyleneimine for macrophage-specific delivery of interleukin-4 plasmids (pIL-4), forming GNPs-pIL-4 for local intramuscular injection. GNPs-pIL-4 had uniform size, positive surface charge, and strong nucleic acid loading capacity ( K d : 25 nanomolar). In vivo, GNPs-pIL-4 reshaped the ischemic microenvironment by inducing reparative M2 macrophage polarization. Mediated by macrophages, GNPs-pIL-4 improved muscle contractility, delayed strength loss, and enhanced blood perfusion and oxygen saturation. Mechanistically, GNPs-pIL-4 specifically turned on the oncostatin M–mediated macrophage-endothelium communication and then activated the angiogenesis, with increased endothelial sprouting, migration, and tube formation. These effects attributed to the down-regulated S -nitrosoglutathione reductase expression, thereby increasing S-nitrosylation at the C209 site of endoglin. GNPs-pIL-4 represents a promising gene therapy strategy for PAD.
- 14 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (33)
Open AccessGNPs-pIL-4 reprograms macrophage polarization and activates the OSM/GSNOR/ENG axis to improve angiogenesis in ischemic limbs
Therapeutic angiogenesis based on gene therapies is a potential peripheral artery disease (PAD) treatment yet needs a more stable, efficient, and high-affinity delivery vector and an optimized delivery strategy. Here, we engineered three-dimensional graphene nanoparticles modified with folic acid and polyethyleneimine for macrophage-specific delivery of interleukin-4 plasmids (pIL-4), forming GNPs-pIL-4 for local intramuscular injection. GNPs-pIL-4 had uniform size, positive surface charge, and strong nucleic acid loading capacity ( K d : 25 nanomolar). In vivo, GNPs-pIL-4 reshaped the ischemic microenvironment by inducing reparative M2 macrophage polarization. Mediated by macrophages, GNPs-pIL-4 improved muscle contractility, delayed strength loss, and enhanced blood perfusion and oxygen saturation. Mechanistically, GNPs-pIL-4 specifically turned on the oncostatin M–mediated macrophage-endothelium communication and then activated the angiogenesis, with increased endothelial sprouting, migration, and tube formation. These effects attributed to the down-regulated S -nitrosoglutathione reductase expression, thereby increasing S-nitrosylation at the C209 site of endoglin. GNPs-pIL-4 represents a promising gene therapy strategy for PAD.
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Wen-Jing-Tang and its bioactive component rutaecarpine ameliorate cold-induced uterine smooth muscle contraction in rats by stabilizing PRDX4 and inhibiting chaperone-mediated autophagy
Background: Primary dysmenorrhea (PD) is often exacerbated by cold exposure, with excessive uterine contraction and microcirculatory dysfunction. Wen-Jing-Tang (WJT), a Traditional Chinese Medicine formula, is clinically used to treat cold-induced PD, however, its underlying pharmacological mechanisms remain unelucidated.Purpose:To explore the underlying pharmacological mechanisms of WJT.Study design :Integrated approaches including uterine function assays, primary uterine smooth muscle cell (pUSMC) experiments, and multi-omics analysis were employed to investigate the pharmacological mechanisms of WJT.Methods: A cold exposure model was established. Laser Doppler perfusion imaging and intravital microscopy assessed uterine microcirculation. Cellular thermal shift assay, thermal proteome profiling, molecular docking, molecular dynamics simulations and surface plasmon resonance were utilized to analyze the binding conformation and stability of the rutaecarpine-peroxiredoxin 4 (RUT-PRDX4) complex. Furthermore, lysosome isolation, and co-immunoprecipitation were conducted to investigate PRDX4 stability and its interaction with chaperones.Results: WJT improved cold-induced uterine arterial constriction and uterine excessive contractions, which were associated with modulating the “thermoreceptor-locus coeruleus (LC)-norepinephrine (NE)-reactive oxygen species (ROS)” axis. RUT was identified as the core active monomer of WJT, which directly bound to PRDX4 at the R96 site, stabilizing PRDX4 by enhancing its interactions with molecular chaperones. This interaction inhibited NE-induced lysosome-associated membrane protein 2A upregulation and prevented PRDX4 degradation via the chaperone-mediated autophagy (CMA) pathway. Consequently, PRDX4 restored antioxidant capacity, scavenged excess ROS in pUSMCs, and alleviated excessive uterine smooth muscle contractions.Conclusions: WJT effectively alleviates cold-induced uterine microcirculatory dysfunction and excessive contractions. WJT active component RUT binds to PRDX4. This prevents NE-induced PRDX4 degradation via the CMA pathway, stabilizing PRDX4 and scavenging ROS to alleviate contractions.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessWen-Jing-Tang and its bioactive component rutaecarpine ameliorate cold-induced uterine smooth muscle contraction in rats by stabilizing PRDX4 and inhibiting chaperone-mediated autophagy
Background: Primary dysmenorrhea (PD) is often exacerbated by cold exposure, with excessive uterine contraction and microcirculatory dysfunction. Wen-Jing-Tang (WJT), a Traditional Chinese Medicine formula, is clinically used to treat cold-induced PD, however, its underlying pharmacological mechanisms remain unelucidated.Purpose:To explore the underlying pharmacological mechanisms of WJT.Study design :Integrated approaches including uterine function assays, primary uterine smooth muscle cell (pUSMC) experiments, and multi-omics analysis were employed to investigate the pharmacological mechanisms of WJT.Methods: A cold exposure model was established. Laser Doppler perfusion imaging and intravital microscopy assessed uterine microcirculation. Cellular thermal shift assay, thermal proteome profiling, molecular docking, molecular dynamics simulations and surface plasmon resonance were utilized to analyze the binding conformation and stability of the rutaecarpine-peroxiredoxin 4 (RUT-PRDX4) complex. Furthermore, lysosome isolation, and co-immunoprecipitation were conducted to investigate PRDX4 stability and its interaction with chaperones.Results: WJT improved cold-induced uterine arterial constriction and uterine excessive contractions, which were associated with modulating the “thermoreceptor-locus coeruleus (LC)-norepinephrine (NE)-reactive oxygen species (ROS)” axis. RUT was identified as the core active monomer of WJT, which directly bound to PRDX4 at the R96 site, stabilizing PRDX4 by enhancing its interactions with molecular chaperones. This interaction inhibited NE-induced lysosome-associated membrane protein 2A upregulation and prevented PRDX4 degradation via the chaperone-mediated autophagy (CMA) pathway. Consequently, PRDX4 restored antioxidant capacity, scavenged excess ROS in pUSMCs, and alleviated excessive uterine smooth muscle contractions.Conclusions: WJT effectively alleviates cold-induced uterine microcirculatory dysfunction and excessive contractions. WJT active component RUT binds to PRDX4. This prevents NE-induced PRDX4 degradation via the CMA pathway, stabilizing PRDX4 and scavenging ROS to alleviate contractions.
- Open Access
- 6 June 2026
- Published by Elsevier in Redox Biology
- Vol. 95, 104250
Fenofibrate attenuates hyperhomocysteinemia-potentiated thrombosis by restoring platelet fatty acid β-oxidation
- 6 June 2026
- Published by Elsevier in Redox Biology
- Vol. 95, 104250
Open AccessFenofibrate attenuates hyperhomocysteinemia-potentiated thrombosis by restoring platelet fatty acid β-oxidation
- 18 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 153, 157845
Dehydrocavidine alleviates lipopolysaccharide-induced acute liver injury by activating Nrf2 signaling pathway to inhibit hepatocyte ferroptosis
- 18 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 153, 157845
Dehydrocavidine alleviates lipopolysaccharide-induced acute liver injury by activating Nrf2 signaling pathway to inhibit hepatocyte ferroptosis
- 1 May 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 70 (5) , 364-378
Farnesoid X Receptor Protects Murine Lung against IL-6–promoted Ferroptosis Induced by Polyriboinosinic-Polyribocytidylic Acid
Various infections trigger a storm of proinflammatory cytokines in which IL-6 acts as a major contributor and leads to diffuse alveolar damage in patients. However, the metabolic regulatory mechanisms of IL-6 in lung injury remain unclear. Polyriboinosinic-polyribocytidylic acid [poly(I:C)] activates pattern recognition receptors involved in viral sensing and is widely used in alternative animal models of RNA virus–infected lung injury. In this study, intratracheal instillation of poly(I:C) with or without an IL-6–neutralizing antibody model was combined with metabonomics, transcriptomics, and so forth to explore the underlying molecular mechanisms of IL-6–exacerbated lung injury. We found that poly(I:C) increased the IL-6 concentration, and the upregulated IL-6 further induced lung ferroptosis, especially in alveolar epithelial type II cells. Meanwhile, lung regeneration was impaired. Mechanistically, metabolomic analysis showed that poly(I:C) significantly decreased glycolytic metabolites and increased bile acid intermediate metabolites that inhibited the bile acid nuclear receptor farnesoid X receptor (FXR), which could be reversed by IL-6–neutralizing antibody. In the ferroptosis microenvironment, IL-6 receptor monoclonal antibody tocilizumab increased FXR expression and subsequently increased the Yes-associated protein (YAP) concentration by enhancing PKM2 in A549 cells. FXR agonist GW4064 and liquiritin, a potential natural herbal ingredient as an FXR regulator, significantly attenuated lung tissue inflammation and ferroptosis while promoting pulmonary regeneration. Together, the findings of the present study provide the evidence that IL-6 promotes ferroptosis and impairs regeneration of alveolar epithelial type II cells during poly(I:C)-induced murine lung injury by regulating the FXR-PKM2-YAP axis. Targeting FXR represents a promising therapeutic strategy for IL-6–associated inflammatory lung injury.
- 1 May 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 70 (5) , 364-378
Farnesoid X Receptor Protects Murine Lung against IL-6–promoted Ferroptosis Induced by Polyriboinosinic-Polyribocytidylic Acid
Various infections trigger a storm of proinflammatory cytokines in which IL-6 acts as a major contributor and leads to diffuse alveolar damage in patients. However, the metabolic regulatory mechanisms of IL-6 in lung injury remain unclear. Polyriboinosinic-polyribocytidylic acid [poly(I:C)] activates pattern recognition receptors involved in viral sensing and is widely used in alternative animal models of RNA virus–infected lung injury. In this study, intratracheal instillation of poly(I:C) with or without an IL-6–neutralizing antibody model was combined with metabonomics, transcriptomics, and so forth to explore the underlying molecular mechanisms of IL-6–exacerbated lung injury. We found that poly(I:C) increased the IL-6 concentration, and the upregulated IL-6 further induced lung ferroptosis, especially in alveolar epithelial type II cells. Meanwhile, lung regeneration was impaired. Mechanistically, metabolomic analysis showed that poly(I:C) significantly decreased glycolytic metabolites and increased bile acid intermediate metabolites that inhibited the bile acid nuclear receptor farnesoid X receptor (FXR), which could be reversed by IL-6–neutralizing antibody. In the ferroptosis microenvironment, IL-6 receptor monoclonal antibody tocilizumab increased FXR expression and subsequently increased the Yes-associated protein (YAP) concentration by enhancing PKM2 in A549 cells. FXR agonist GW4064 and liquiritin, a potential natural herbal ingredient as an FXR regulator, significantly attenuated lung tissue inflammation and ferroptosis while promoting pulmonary regeneration. Together, the findings of the present study provide the evidence that IL-6 promotes ferroptosis and impairs regeneration of alveolar epithelial type II cells during poly(I:C)-induced murine lung injury by regulating the FXR-PKM2-YAP axis. Targeting FXR represents a promising therapeutic strategy for IL-6–associated inflammatory lung injury.
- Open Access
- 1 February 2024
- Published by Elsevier in Engineering
- Vol. 38, 77-99
Natural Products Improve Organ Microcirculation Dysfunction Following Ischemia/Reperfusion- and Lipopolysaccharide-Induced Disturbances: Mechanistic and Therapeutic Views
- 1 February 2024
- Published by Elsevier in Engineering
- Vol. 38, 77-99
Open AccessNatural Products Improve Organ Microcirculation Dysfunction Following Ischemia/Reperfusion- and Lipopolysaccharide-Induced Disturbances: Mechanistic and Therapeutic Views
- Open Access
- 17 May 2023
- Published by Wiley in Rheumatology & Autoimmunity
- Vol. 3 (3) , 131-139
Role of β2‐glycoprotein I in the pathogenesis of the antiphospholipid syndrome
Antiphospholipid syndrome (APS) is typically characterized by increased levels of three classes of antiphospholipid antibodies, namely lupus anticoagulant, anti‐β2‐glycoprotein I (anti‐β2GPI), and anticardiolipin antibodies. β2‐Glycoprotein (β2GPI) is a phospholipid‐binding protein composed of five domains (DI–V) and a major antigen in APS. β2GPI is expressed on the surfaces of several cell types, including endothelial cells, monocytes, trophoblast cells, and platelets. Its binding to the anti‐β2GPI antibody triggers downstream signaling events and ultimately exerts a variety of cellular effects. β2GPI modulates hemostasis and the complement system, as well as playing an important role in APS‐associated vascular injury. Therefore, studying β2GPI will help elucidate the pathogenesis of APS and improve the treatment of patients with this condition. This review will mainly focus on the structure and function of β2GPI, as well as its implication in the pathogenesis of APS.
- 17 May 2023
- Published by Wiley in Rheumatology & Autoimmunity
- Vol. 3 (3) , 131-139
Open AccessRole of β2‐glycoprotein I in the pathogenesis of the antiphospholipid syndrome
Antiphospholipid syndrome (APS) is typically characterized by increased levels of three classes of antiphospholipid antibodies, namely lupus anticoagulant, anti‐β2‐glycoprotein I (anti‐β2GPI), and anticardiolipin antibodies. β2‐Glycoprotein (β2GPI) is a phospholipid‐binding protein composed of five domains (DI–V) and a major antigen in APS. β2GPI is expressed on the surfaces of several cell types, including endothelial cells, monocytes, trophoblast cells, and platelets. Its binding to the anti‐β2GPI antibody triggers downstream signaling events and ultimately exerts a variety of cellular effects. β2GPI modulates hemostasis and the complement system, as well as playing an important role in APS‐associated vascular injury. Therefore, studying β2GPI will help elucidate the pathogenesis of APS and improve the treatment of patients with this condition. This review will mainly focus on the structure and function of β2GPI, as well as its implication in the pathogenesis of APS.
- Open Access
- 14 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (15) , eadd2632
CD34 + cell–derived fibroblast-macrophage cross-talk drives limb ischemia recovery through the OSM-ANGPTL signaling axis
CD34 + cells improve the perfusion and function of ischemic limbs in humans and mice. However, there is no direct evidence of the differentiation potential and functional role of these cells in the ischemic muscle microenvironment. Here, we combined the single-cell RNA sequencing and genetic lineage tracing technology, then provided exact single-cell atlases of normal and ischemic limb tissues in human and mouse, and consequently found that bone marrow (BM)–derived macrophages with antigen-presenting function migrated to the ischemic site, while resident macrophages underwent apoptosis. The macrophage oncostatin M (OSM) regulatory pathway was specifically turned on by ischemia. Simultaneously, BM CD34 + -derived proregenerative fibroblasts were recruited to the ischemia niche, where they received macrophage-released OSM and promoted angiopoietin-like protein–associated angiogenesis. These findings provided mechanisms on the cellular events and cell-cell communications during tissue ischemia and regeneration and provided evidence that CD34 + cells serve as fibroblast progenitors promoting tissue regeneration.
- 14 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (15) , eadd2632
Open AccessCD34 + cell–derived fibroblast-macrophage cross-talk drives limb ischemia recovery through the OSM-ANGPTL signaling axis
CD34 + cells improve the perfusion and function of ischemic limbs in humans and mice. However, there is no direct evidence of the differentiation potential and functional role of these cells in the ischemic muscle microenvironment. Here, we combined the single-cell RNA sequencing and genetic lineage tracing technology, then provided exact single-cell atlases of normal and ischemic limb tissues in human and mouse, and consequently found that bone marrow (BM)–derived macrophages with antigen-presenting function migrated to the ischemic site, while resident macrophages underwent apoptosis. The macrophage oncostatin M (OSM) regulatory pathway was specifically turned on by ischemia. Simultaneously, BM CD34 + -derived proregenerative fibroblasts were recruited to the ischemia niche, where they received macrophage-released OSM and promoted angiopoietin-like protein–associated angiogenesis. These findings provided mechanisms on the cellular events and cell-cell communications during tissue ischemia and regeneration and provided evidence that CD34 + cells serve as fibroblast progenitors promoting tissue regeneration.
- Open Access
- 13 March 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-16
B cell-derived anti-beta 2 glycoprotein I antibody mediates hyperhomocysteinemia-aggravated hypertensive glomerular lesions by triggering ferroptosis
Hyperhomocysteinemia (HHcy) is a risk factor for chronic kidney diseases (CKDs) that affects about 85% CKD patients. HHcy stimulates B cells to secrete pathological antibodies, although it is unknown whether this pathway mediates kidney injury. In HHcy-treated 2-kidney, 1-clip (2K1C) hypertensive murine model, HHcy-activated B cells secreted anti-beta 2 glycoprotein I (β2GPI) antibodies that deposited in glomerular endothelial cells (GECs), exacerbating glomerulosclerosis and reducing renal function. Mechanistically, HHcy 2K1C mice increased phosphatidylethanolamine (PE) (18:0/20:4, 18:0/22:6, 16:0/20:4) in kidney tissue, as determined by lipidomics. GECs oxidative lipidomics validated the increase of oxidized phospholipids upon Hcy-activated B cells culture medium (Hcy-B CM) treatment, including PE (18:0/20:4 + 3[O], PE (18:0a/22:4 + 1[O], PE (18:0/22:4 + 2[O] and PE (18:0/22:4 + 3[O]). PE synthases ethanolamine kinase 2 (etnk2) and ethanolamine-phosphate cytidylyltransferase 2 (pcyt2) were increased in the kidney GECs of HHcy 2K1C mice and facilitated polyunsaturated PE synthesis to act as lipid peroxidation substrates. In HHcy 2K1C mice and Hcy-B CM-treated GECs, the oxidative environment induced by iron accumulation and the insufficient clearance of lipid peroxides caused by transferrin receptor (TFR) elevation and down-regulation of SLC7A11/glutathione peroxidase 4 (GPX4) contributed to GECs ferroptosis of the kidneys. In vivo, pharmacological depletion of B cells or inhibition of ferroptosis mitigated the HHcy-aggravated hypertensive renal injury. Consequently, our findings uncovered a novel mechanism by which B cell-derived pathogenic anti-β2GPI IgG generated by HHcy exacerbated hypertensive kidney damage by inducing GECs ferroptosis. Targeting B cells or ferroptosis may be viable therapeutic strategies for ameliorating lipid peroxidative renal injury in HHcy patients with hypertensive nephropathy.
- 13 March 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-16
Open AccessB cell-derived anti-beta 2 glycoprotein I antibody mediates hyperhomocysteinemia-aggravated hypertensive glomerular lesions by triggering ferroptosis
Hyperhomocysteinemia (HHcy) is a risk factor for chronic kidney diseases (CKDs) that affects about 85% CKD patients. HHcy stimulates B cells to secrete pathological antibodies, although it is unknown whether this pathway mediates kidney injury. In HHcy-treated 2-kidney, 1-clip (2K1C) hypertensive murine model, HHcy-activated B cells secreted anti-beta 2 glycoprotein I (β2GPI) antibodies that deposited in glomerular endothelial cells (GECs), exacerbating glomerulosclerosis and reducing renal function. Mechanistically, HHcy 2K1C mice increased phosphatidylethanolamine (PE) (18:0/20:4, 18:0/22:6, 16:0/20:4) in kidney tissue, as determined by lipidomics. GECs oxidative lipidomics validated the increase of oxidized phospholipids upon Hcy-activated B cells culture medium (Hcy-B CM) treatment, including PE (18:0/20:4 + 3[O], PE (18:0a/22:4 + 1[O], PE (18:0/22:4 + 2[O] and PE (18:0/22:4 + 3[O]). PE synthases ethanolamine kinase 2 (etnk2) and ethanolamine-phosphate cytidylyltransferase 2 (pcyt2) were increased in the kidney GECs of HHcy 2K1C mice and facilitated polyunsaturated PE synthesis to act as lipid peroxidation substrates. In HHcy 2K1C mice and Hcy-B CM-treated GECs, the oxidative environment induced by iron accumulation and the insufficient clearance of lipid peroxides caused by transferrin receptor (TFR) elevation and down-regulation of SLC7A11/glutathione peroxidase 4 (GPX4) contributed to GECs ferroptosis of the kidneys. In vivo, pharmacological depletion of B cells or inhibition of ferroptosis mitigated the HHcy-aggravated hypertensive renal injury. Consequently, our findings uncovered a novel mechanism by which B cell-derived pathogenic anti-β2GPI IgG generated by HHcy exacerbated hypertensive kidney damage by inducing GECs ferroptosis. Targeting B cells or ferroptosis may be viable therapeutic strategies for ameliorating lipid peroxidative renal injury in HHcy patients with hypertensive nephropathy.
- Top Cited Papers
- 28 October 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (10) , 807-824
PHB2 Maintains the Contractile Phenotype of VSMCs by Counteracting PKM2 Splicing
Background: Phenotypic transition of vascular smooth muscle cells (VSMCs) accounts for the pathogenesis of a variety of vascular diseases during the early stage. Recent studies indicate the metabolic reprogramming may be involved in VSMC phenotypic transition. However, the definite molecules that link energy metabolism to distinct VSMC phenotype remain elusive. Methods: A carotid artery injury model was used to study postinjury neointima formation as well as VSMC phenotypic transition in vivo. RNA-seq analysis, cell migration assay, collagen gel contraction assay, wire myography assay, immunoblotting, protein interactome analysis, co-immunoprecipitation, and mammalian 2-hybrid assay were performed to clarify the phenotype and elucidate the molecular mechanisms. Results: We collected cell energy-regulating genes by using Gene Ontology annotation and applied RNA-Seq analysis of transforming growth factor-β or platelet-derived growth factor BB stimulated VSMCs. Six candidate genes were overlapped from energy metabolism-related genes and genes reciprocally upregulated by transforming growth factor-β and downregulated by platelet-derived growth factor BB. Among them, prohibitin 2 has been reported to regulate mitochondrial oxidative phosphorylation. Indeed, prohibitin 2-deficient VSMCs lost the contractile phenotype as evidenced by reduced contractile proteins. Consistently, Phb2 SMCKO mice were more susceptible to postinjury VSMC proliferation and neointima formation compared with Phb2 flox/flox mice. Further protein interactome analysis, co-immunoprecipitation, and mammalian 2-hybrid assay revealed that prohibitin 2, through its C-terminus, directly interacts with hnRNPA1, a key modulator of pyruvate kinase M1/2 (PKM) mRNA splicing that promotes PKM2 expression and glycolysis. Prohibitin 2 deficiency facilitated PKM1/2 mRNA splicing and reversion from PKM1 to PKM2, and enhanced glycolysis in VSMCs. Blocking prohibitin 2–hnRNPA1 interaction resulted in increased PKM2 expression, enhanced glycolysis, repressed contractile marker genes expression in VSMCs, as well as aggravated postinjury neointima formation in vivo. Conclusions: Prohibitin 2 maintains VSMC contractile phenotype by interacting with hnRNPA1 to counteract hnRNPA1-mediated PKM alternative splicing and glucose metabolic reprogramming.
- 28 October 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (10) , 807-824
Top Cited PapersPHB2 Maintains the Contractile Phenotype of VSMCs by Counteracting PKM2 Splicing
Background: Phenotypic transition of vascular smooth muscle cells (VSMCs) accounts for the pathogenesis of a variety of vascular diseases during the early stage. Recent studies indicate the metabolic reprogramming may be involved in VSMC phenotypic transition. However, the definite molecules that link energy metabolism to distinct VSMC phenotype remain elusive. Methods: A carotid artery injury model was used to study postinjury neointima formation as well as VSMC phenotypic transition in vivo. RNA-seq analysis, cell migration assay, collagen gel contraction assay, wire myography assay, immunoblotting, protein interactome analysis, co-immunoprecipitation, and mammalian 2-hybrid assay were performed to clarify the phenotype and elucidate the molecular mechanisms. Results: We collected cell energy-regulating genes by using Gene Ontology annotation and applied RNA-Seq analysis of transforming growth factor-β or platelet-derived growth factor BB stimulated VSMCs. Six candidate genes were overlapped from energy metabolism-related genes and genes reciprocally upregulated by transforming growth factor-β and downregulated by platelet-derived growth factor BB. Among them, prohibitin 2 has been reported to regulate mitochondrial oxidative phosphorylation. Indeed, prohibitin 2-deficient VSMCs lost the contractile phenotype as evidenced by reduced contractile proteins. Consistently, Phb2 SMCKO mice were more susceptible to postinjury VSMC proliferation and neointima formation compared with Phb2 flox/flox mice. Further protein interactome analysis, co-immunoprecipitation, and mammalian 2-hybrid assay revealed that prohibitin 2, through its C-terminus, directly interacts with hnRNPA1, a key modulator of pyruvate kinase M1/2 (PKM) mRNA splicing that promotes PKM2 expression and glycolysis. Prohibitin 2 deficiency facilitated PKM1/2 mRNA splicing and reversion from PKM1 to PKM2, and enhanced glycolysis in VSMCs. Blocking prohibitin 2–hnRNPA1 interaction resulted in increased PKM2 expression, enhanced glycolysis, repressed contractile marker genes expression in VSMCs, as well as aggravated postinjury neointima formation in vivo. Conclusions: Prohibitin 2 maintains VSMC contractile phenotype by interacting with hnRNPA1 to counteract hnRNPA1-mediated PKM alternative splicing and glucose metabolic reprogramming.